Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats

American Journal of Nephrology

Volumn 24, Issue 3, 2004, Pages 352-359

  Dipetrillo, Keith ^a,b   Gesek, Frank A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Hypertrophy; Pentoxifylline; Proximal tubule; Sodium retention; Tumor necrosis factor

Indexed keywords

MESSENGER RNA; PENTOXIFYLLINE; PROTEIN; SODIUM; STREPTOZOCIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; KIDNEY DISTAL TUBULE; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL DIABETES; SODIUM EXCRETION; SODIUM RETENTION; STREPTOZOCIN DIABETES; URINARY EXCRETION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HYPERTROPHY; KIDNEY; MALE; PENTOXIFYLLINE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4043082724     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079121     Document Type: Article

References (37)

1. Molitch ME, DeFronzo RA, Franz MA, et al: Diabetic nephropathy. Diabetes Care 2000;23(suppl 1):S69-S73.
2. Rasch R, Torffvit O, Bachmann S, et al: Tamm-Horsfall glycoprotein in streptozotocin diabetic rats: A study of kidney in situ hybridization, immunohistochemistry, and urinary excretion. Diabetologia 1995;38:525-535.
3. Rasch R, Dorup J: Quantitative morphology of the rat kidney during diabetes mellitus and insulin treatment. Diabetologia 1997;40:802-809.
4. Sugimoto H, Shikata K, Wada J, et al: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999;42:878-886.
5. Hasegawa G, Nakano K, Sawada M, et al: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991;40:1007-1012.
6. Reeves WB, Andreoli TE: Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000;97:7667-7669.
7. Flyvbjerg A: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000;43:1205-1223.
8. Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(suppl 2):64-78.
9. Nakamura T, Fukui M, Ebihara I, et al: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993;42:450-456.
10. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.
11. Ziyadeh FN, Hoffman BB, Han DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factorbeta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
12. Haylor J, Hickling H, El Eter E, et al: JB3, an IGF-I receptor antagonist, inhibits early renal growth in diabetic and uninephrectomized rats. J Am Soc Nephrol 2000;11:2027-2035.
13. Wang SN, Lapage J, Hirschberg R: Glomerular ultrafiltration of IGF-I may contribute to increased renal sodium retention in diabetic nephropathy. J Lab Clin Med 1999;134:154-160.
14. Gronbaek H, Volmers P, Bjorn SF, et al: Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats. Am J Physiol 1997;272:E918-E924.
15. DiPetrillo K, Coutermarsh B, Gesek FA: Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 2003;284:F113-F121.
16. Cottone S, Vadala A, Vella MC, et al: Comparison of tumour necrosis factor and endothelin-1 between essential and renal hypertensive patients. J Hum Hypertens 1998;12:351-354.
17. Navarro JF, Mora C, Rivero A, et al: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 1999;33:458-463.
18. Zabel P, Schade FU, Schlaak M: Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 1993;187:447-463.
19. Mohring J, Mohring B: Evaluation of sodium and potassium balance in rats. J Appl Physiol 1972;33:688-692.
20. Zhou MS, Nishida Y, Yoneyama H, et al: Potassium supplementation increases sodium excretion and nitric oxide production in hypertensive Dahl rats. Clin Exp Hypertens 1999;21:1397-1411.
21. Thomson SC, Deng A, Bao D, et al: Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 2001;107:217-224.
22. Szatmary Z: Tumor necrosis factor-alpha: Molecular-biological aspects minireview. Neoplasma 1999:46:257-266.
23. Yu HC, Burrell LM, Black MJ, et al: Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998;98:2621-2628.
24. Allen TJ, Waldron MJ, Casley D, et al: Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes 1997;46:19-24.
25. Gugliucci A, Bendayan M: Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996;39:149-160.
26. Oldfield MD, Bach LA, Forbes JM, et al: Advanced glycation end products cause epithelialmyofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001;108:1853-1863.
27. Morcos M, Sayed AA, Bierhaus A, et al: Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002;51:3532-3544.
28. Ye J, Wang L, Zhang X, et al: Inhibition of TNF-alpha gene expression and bioactivity by site-specific transcription factor-binding oligonucleotides. Am J Physiol Lung Cell Mol Physiol, 2003;284:L386-L394.
29. Kang YJ, Lee BK, Lee YS, et al: Suppression of tumor necrosis factor-alpha and inducible nitric oxide synthase gene expression by THI 52, a new synthetic naphthyl-benzylisoquinoline alkaloid. Biochem Pharmacol 2003;65:457-464.
30. Corssmit EP, Romijn JA, Endert E, Sauerwein HP: Pentoxifylline inhibits basal glucose production in humans. J Appl Physiol 1994;77:2767-2772.
31. Corssmit EP, Romijn JA, Endert E, Sauerwein HP: Modulation of glucose production by indomethacin and pentoxifylline in healthy humans. Metabolism 1996;45:1458-1465.
32. Wang W, Wang P, Chaudry IH: Pentoxifylline increases gut ketogenesis following trauma and hemorrhagic shock. Crit Care Med 1998;26:101-107.
33. Imanishi M, Yoshioka K, Okumura M, et al: Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care 2001;24:111-116.
34. Baumgartl HJ, Sigl G, Banholzer P, et al: On the prognosis of IDDM patients with large kidneys. Nephrol Dial Transplant 1998;13:630-634.
35. O'Hare JA, Ferriss JB, Brady D, et al: Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy. Hypertension 1985;7:II43-II48.
36. Messerli FH, Schmieder RE, Weir MR: Salt. A perpetrator of hypertensive target organ disease? Arch Intern Med 1997;157:2449-2452.
37. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR, et al: Pentoxifylline reduces proteinuria in insulin-dependent and non insulin- dependent diabetic patients. Clin Nephrol 1995;43:116-121.